Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
SUMMARY
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) pipeline Target constitutes close to 48 molecules. Out of which approximately 37 molecules are developed by companies and remaining by the universities/institutes. The latest report Bromodomain Containing Protein 4 - Drugs In Development, 2022, outlays comprehensive information on the Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Bromodomain-containing protein 4 is a protein encoded by the BRD4 gene. It plays a key role in transmission of epigenetic memory across cell divisions and transcription regulation. It promotes phosphorylation of Ser-2 of the C-terminal domain (CTD) of RNA polymerase II. It acts as a regulator of p53/TP53-mediated transcription. The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 4, 7, 2, 18 and 4 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 6 and 5 molecules, respectively.
Report covers products from therapy areas Oncology, Infectious Disease, Dermatology, Immunology, Cardiovascular, Genetic Disorders, Genito Urinary System And Sex Hormones and Musculoskeletal Disorders which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Solid Tumor, Ovarian Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Myelofibrosis, Triple-Negative Breast Cancer (TNBC), Lymphoma, Pancreatic Cancer, Diffuse Large B-Cell Lymphoma, Fallopian Tube Cancer, Melanoma, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Peritoneal Cancer, Small-Cell Lung Cancer, Breast Cancer, Colorectal Cancer, Human Immunodeficiency Virus (HIV) Infections (AIDS), Lung Cancer, Non-Hodgkin Lymphoma, Colon Cancer, Coronavirus Disease 2019 (COVID-19), Epithelial Ovarian Cancer, Follicular Lymphoma, Hematological Tumor, Hepatocellular Carcinoma, Leukemia, Myeloproliferative Disorders, Neuroblastoma, Non-Small Cell Lung Cancer, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Rheumatoid Arthritis, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Advanced Malignancy, Atopic Dermatitis (Atopic Eczema), B-Cell Non-Hodgkin Lymphoma, Basal Cell Carcinoma (Basal Cell Epithelioma), Cardiovascular Risk Factors, Cervical Cancer, Chronic Kidney Disease (Chronic Renal Failure), Chronic Lymphocytic Leukemia (CLL), Coronary Artery Disease (CAD) (Ischemic Heart Disease), Dermatitis (Eczema), Fabry Disease, Facioscapulohumeral Muscular Dystrophy (FSHD), Glioblastoma Multiforme (GBM), Malignant Mesothelioma, Malignant Neoplasms, Mantle Cell Lymphoma, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Liver Cancer, Pancreatic Ductal Adenocarcinoma, Peripheral Arterial Disease (PAD)/Peripheral Vascular Disease (PVD), Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), Primary Mediastinal B-Cell Lymphoma, Prostate Cancer, Psoriasis, Pulmonary Arterial Hypertension, Renal Cell Carcinoma, Systemic Sclerosis (Scleroderma), Unspecified B-Cell Lymphomas, Unspecified Cancer, Uterine Cancer, Uveal Melanoma, Vaginal Cancer, Vitiligo and Vulvar Cancer.
Furthermore, this report also reviews key players involved in Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) pipeline Target constitutes close to 48 molecules. Out of which approximately 37 molecules are developed by companies and remaining by the universities/institutes. The latest report Bromodomain Containing Protein 4 - Drugs In Development, 2022, outlays comprehensive information on the Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Bromodomain-containing protein 4 is a protein encoded by the BRD4 gene. It plays a key role in transmission of epigenetic memory across cell divisions and transcription regulation. It promotes phosphorylation of Ser-2 of the C-terminal domain (CTD) of RNA polymerase II. It acts as a regulator of p53/TP53-mediated transcription. The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 4, 7, 2, 18 and 4 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 6 and 5 molecules, respectively.
Report covers products from therapy areas Oncology, Infectious Disease, Dermatology, Immunology, Cardiovascular, Genetic Disorders, Genito Urinary System And Sex Hormones and Musculoskeletal Disorders which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Solid Tumor, Ovarian Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Myelofibrosis, Triple-Negative Breast Cancer (TNBC), Lymphoma, Pancreatic Cancer, Diffuse Large B-Cell Lymphoma, Fallopian Tube Cancer, Melanoma, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Peritoneal Cancer, Small-Cell Lung Cancer, Breast Cancer, Colorectal Cancer, Human Immunodeficiency Virus (HIV) Infections (AIDS), Lung Cancer, Non-Hodgkin Lymphoma, Colon Cancer, Coronavirus Disease 2019 (COVID-19), Epithelial Ovarian Cancer, Follicular Lymphoma, Hematological Tumor, Hepatocellular Carcinoma, Leukemia, Myeloproliferative Disorders, Neuroblastoma, Non-Small Cell Lung Cancer, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Rheumatoid Arthritis, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Advanced Malignancy, Atopic Dermatitis (Atopic Eczema), B-Cell Non-Hodgkin Lymphoma, Basal Cell Carcinoma (Basal Cell Epithelioma), Cardiovascular Risk Factors, Cervical Cancer, Chronic Kidney Disease (Chronic Renal Failure), Chronic Lymphocytic Leukemia (CLL), Coronary Artery Disease (CAD) (Ischemic Heart Disease), Dermatitis (Eczema), Fabry Disease, Facioscapulohumeral Muscular Dystrophy (FSHD), Glioblastoma Multiforme (GBM), Malignant Mesothelioma, Malignant Neoplasms, Mantle Cell Lymphoma, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Liver Cancer, Pancreatic Ductal Adenocarcinoma, Peripheral Arterial Disease (PAD)/Peripheral Vascular Disease (PVD), Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), Primary Mediastinal B-Cell Lymphoma, Prostate Cancer, Psoriasis, Pulmonary Arterial Hypertension, Renal Cell Carcinoma, Systemic Sclerosis (Scleroderma), Unspecified B-Cell Lymphomas, Unspecified Cancer, Uterine Cancer, Uveal Melanoma, Vaginal Cancer, Vitiligo and Vulvar Cancer.
Furthermore, this report also reviews key players involved in Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4)
- The report reviews Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics and enlists all their major and minor projects
- The report assesses Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Overview
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Companies Involved in Therapeutics Development
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Drug Profiles
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Dormant Products
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Discontinued Products
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Product Development Milestones
Featured News & Press Releases
Apr 08, 2022: Phio Pharmaceuticals presents positive new data on PH-894 demonstrating antitumor efficacy in model of PD-1 refractory disease at the AACR Annual Meeting 2022
Mar 30, 2022: VYNE Reports positive preclinical data for intra-articular injection of pan-BET inhibitor, VYN201, in an in vivo model of rheumatoid arthritis
Mar 17, 2022: Apabetalone’s Positive Impact on Pulmonary Arterial Hypertension Published in the American Journal of Respiratory and Critical Care Medicine
Mar 08, 2022: Phio Pharmaceuticals announces upcoming presentation of PH-894 data at the AACR Annual Meeting 2022
Mar 07, 2022: VYNE reports positive preclinical data for lead BET Inhibitor, VYN201, in human skin model of vitiligo
Feb 22, 2022: Zenith Epigenetics announces dosing of first cancer patient with a combination of ZEN-3694 + Bristol Myers Squibb’s immune checkpoint inhibitor OPDIVO
Feb 18, 2022: Resverlogix expands Phase IIb apabetalone trial for Covid-19
Feb 15, 2022: Ranok Therapeutics to present at BMO Biopharma spotlight series on protein degraders and other Next Gen
Jan 24, 2022: Ranok Therapeutics announces U.S. FDA clearance to proceed with its first-in-human trial of RNK05047 in patients With advanced solid tumor cancers and lymphomas (CHAMP-1)
Jan 21, 2022: US FDA clears Nuvation Bio’s application for solid tumour therapy
Jan 19, 2022: Resverlogix starts Phase IIb oral Covid-19 drug trial
Jan 18, 2022: Resverlogix announces commencement of patient enrollment and dosing in a phase 2b trial for a promising Canadian-developed COVID-19 treatment
Dec 12, 2021: MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosis
Nov 04, 2021: MorphoSys to present MANIFEST data from expanded hematology-oncology portfolio at the 2021 American Society of Hematology (ASH) Annual Meeting
Nov 04, 2021: Lead BET inhibitor, VYN201, demonstrates improvement in reducing fibrotic tissue mass and overall skin repair outcomes in preclinical study
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Overview
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Companies Involved in Therapeutics Development
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Drug Profiles
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Dormant Products
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Discontinued Products
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Product Development Milestones
Featured News & Press Releases
Apr 08, 2022: Phio Pharmaceuticals presents positive new data on PH-894 demonstrating antitumor efficacy in model of PD-1 refractory disease at the AACR Annual Meeting 2022
Mar 30, 2022: VYNE Reports positive preclinical data for intra-articular injection of pan-BET inhibitor, VYN201, in an in vivo model of rheumatoid arthritis
Mar 17, 2022: Apabetalone’s Positive Impact on Pulmonary Arterial Hypertension Published in the American Journal of Respiratory and Critical Care Medicine
Mar 08, 2022: Phio Pharmaceuticals announces upcoming presentation of PH-894 data at the AACR Annual Meeting 2022
Mar 07, 2022: VYNE reports positive preclinical data for lead BET Inhibitor, VYN201, in human skin model of vitiligo
Feb 22, 2022: Zenith Epigenetics announces dosing of first cancer patient with a combination of ZEN-3694 + Bristol Myers Squibb’s immune checkpoint inhibitor OPDIVO
Feb 18, 2022: Resverlogix expands Phase IIb apabetalone trial for Covid-19
Feb 15, 2022: Ranok Therapeutics to present at BMO Biopharma spotlight series on protein degraders and other Next Gen
Jan 24, 2022: Ranok Therapeutics announces U.S. FDA clearance to proceed with its first-in-human trial of RNK05047 in patients With advanced solid tumor cancers and lymphomas (CHAMP-1)
Jan 21, 2022: US FDA clears Nuvation Bio’s application for solid tumour therapy
Jan 19, 2022: Resverlogix starts Phase IIb oral Covid-19 drug trial
Jan 18, 2022: Resverlogix announces commencement of patient enrollment and dosing in a phase 2b trial for a promising Canadian-developed COVID-19 treatment
Dec 12, 2021: MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosis
Nov 04, 2021: MorphoSys to present MANIFEST data from expanded hematology-oncology portfolio at the 2021 American Society of Hematology (ASH) Annual Meeting
Nov 04, 2021: Lead BET inhibitor, VYN201, demonstrates improvement in reducing fibrotic tissue mass and overall skin repair outcomes in preclinical study
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Indications, 2022 (Contd..1)
Number of Products under Development by Indications, 2022 (Contd..2)
Number of Products under Development by Indications, 2022 (Contd..3)
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Companies, 2022 (Contd..3)
Products under Development by Companies, 2022 (Contd..4)
Products under Development by Companies, 2022 (Contd..5)
Products under Development by Companies, 2022 (Contd..6)
Products under Development by Companies, 2022 (Contd..7)
Products under Development by Companies, 2022 (Contd..8)
Products under Development by Companies, 2022 (Contd..9)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by AbbVie Inc, 2022
Pipeline by Amgen Inc, 2022
Pipeline by Boehringer Ingelheim International GmbH, 2022
Pipeline by Bristol-Myers Squibb Co, 2022
Pipeline by Bromodomain Pharmaceuticals Inc, 2022
Pipeline by C4 Therapeutics Inc, 2022
Pipeline by Checkpoint Therapeutics Inc, 2022
Pipeline by Chia Tai Tianqing Pharmaceutical Group Co Ltd, 2022
Pipeline by Constellation Pharmaceuticals Inc, 2022
Pipeline by ConverGene LLC, 2022
Pipeline by CSPC Pharmaceutical Group Ltd, 2022
Pipeline by Epigene Therapeutics Inc, 2022
Pipeline by Kainos Medicine Inc, 2022
Pipeline by Ningbo Wenda Pharmaceutical Technology Co Ltd, 2022
Pipeline by Nuvation Bio Inc, 2022
Pipeline by OHM Oncology, 2022
Pipeline by Phio Pharmaceuticals Corp, 2022
Pipeline by Plexium Inc, 2022
Pipeline by Plexxikon Inc, 2022
Pipeline by Ranok Therapeutics Co Ltd, 2022
Pipeline by Red Glead Discovery AB, 2022
Pipeline by Resverlogix Corp, 2022
Pipeline by Roivant Sciences Ltd, 2022
Pipeline by Shanghai Haihe Biopharma Co Ltd, 2022
Pipeline by Sierra Oncology Inc, 2022
Pipeline by SignalRx Pharmaceuticals Inc, 2022
Pipeline by VYNE Therapeutics Inc, 2022
Pipeline by Zenith Epigenetics Ltd, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Dormant Products, 2022 (Contd..2)
Dormant Products, 2022 (Contd..3)
Dormant Products, 2022 (Contd..4)
Dormant Products, 2022 (Contd..5)
Discontinued Products, 2022
Discontinued Products, 2022 (Contd..1)
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Indications, 2022 (Contd..1)
Number of Products under Development by Indications, 2022 (Contd..2)
Number of Products under Development by Indications, 2022 (Contd..3)
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Companies, 2022 (Contd..3)
Products under Development by Companies, 2022 (Contd..4)
Products under Development by Companies, 2022 (Contd..5)
Products under Development by Companies, 2022 (Contd..6)
Products under Development by Companies, 2022 (Contd..7)
Products under Development by Companies, 2022 (Contd..8)
Products under Development by Companies, 2022 (Contd..9)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by AbbVie Inc, 2022
Pipeline by Amgen Inc, 2022
Pipeline by Boehringer Ingelheim International GmbH, 2022
Pipeline by Bristol-Myers Squibb Co, 2022
Pipeline by Bromodomain Pharmaceuticals Inc, 2022
Pipeline by C4 Therapeutics Inc, 2022
Pipeline by Checkpoint Therapeutics Inc, 2022
Pipeline by Chia Tai Tianqing Pharmaceutical Group Co Ltd, 2022
Pipeline by Constellation Pharmaceuticals Inc, 2022
Pipeline by ConverGene LLC, 2022
Pipeline by CSPC Pharmaceutical Group Ltd, 2022
Pipeline by Epigene Therapeutics Inc, 2022
Pipeline by Kainos Medicine Inc, 2022
Pipeline by Ningbo Wenda Pharmaceutical Technology Co Ltd, 2022
Pipeline by Nuvation Bio Inc, 2022
Pipeline by OHM Oncology, 2022
Pipeline by Phio Pharmaceuticals Corp, 2022
Pipeline by Plexium Inc, 2022
Pipeline by Plexxikon Inc, 2022
Pipeline by Ranok Therapeutics Co Ltd, 2022
Pipeline by Red Glead Discovery AB, 2022
Pipeline by Resverlogix Corp, 2022
Pipeline by Roivant Sciences Ltd, 2022
Pipeline by Shanghai Haihe Biopharma Co Ltd, 2022
Pipeline by Sierra Oncology Inc, 2022
Pipeline by SignalRx Pharmaceuticals Inc, 2022
Pipeline by VYNE Therapeutics Inc, 2022
Pipeline by Zenith Epigenetics Ltd, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Dormant Products, 2022 (Contd..2)
Dormant Products, 2022 (Contd..3)
Dormant Products, 2022 (Contd..4)
Dormant Products, 2022 (Contd..5)
Discontinued Products, 2022
Discontinued Products, 2022 (Contd..1)
LIST OF FIGURES
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
